Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zora, Nováková"'
Autor:
Ioanna Liatsou, Betelhem Assefa, Wathsala Liyanage, Sharmane Surasinghe, Zora Nováková, Cyril Bařinka, Kathleen Gabrielson, Venu Raman, Dmitri Artemov, Sudath Hapuarachchige
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Prostate cancer (PC) is an aggressive cancer that can progress rapidly and eventually become castrate-resistant prostate cancer (CRPC). Stage IV metastatic castrate-resistant prostate cancer (mCRPC) is an incurable late-stage cancer type with a low 5
Externí odkaz:
https://doaj.org/article/e55e46e0874d464dbbedcee553133c11
Autor:
Zsófia Kutil, Jana Mikešová, Matthes Zessin, Marat Meleshin, Zora Nováková, Glenda Alquicer, Alan Kozikowski, Wolfgang Sippl, Cyril Bařinka, Mike Schutkowski
Publikováno v:
ACS Omega, Vol 4, Iss 22, Pp 19895-19904 (2019)
Externí odkaz:
https://doaj.org/article/3ee89cddfa29420a99c367293a65dbc0
Autor:
Jens, Cardinale, Mareike, Roscher, Martin, Schäfer, Max, Geerlings, Martina, Benešová, Ulrike, Bauder-Wüst, Yvonne, Remde, Matthias, Eder, Zora, Nováková, Lucia, Motlová, Cyril, Barinka, Frederik L, Giesel, Klaus, Kopka
Publikováno v:
Journal of medicinal chemistry. 63(19)
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a
Autor:
Svoboda, Jakub1 (AUTHOR), Berdár, Daniel1 (AUTHOR), Kolenko, Petr1,2 (AUTHOR), Černý, Jiří1 (AUTHOR), Nováková, Zora1 (AUTHOR), Pavlíček, Jiří1 (AUTHOR), Schneider, Bohdan1 (AUTHOR) bohdan.schneider@ibt.cas.cz
Publikováno v:
Acta Crystallographica: Section D, Structural Biology. Jul2023, Vol. 79 Issue 7, p655-665. 11p.
Publikováno v:
Electrophoresis; Mar2006, Vol. 27 Issue 7, p1277-1287, 11p
Autor:
Ronnie C. Mease, Zora Novakova, Ala Lisok, Dhiraj Kumar, Sridhar Nimmagadda, Akhilesh Mishra, Cyril Bařinka
Publikováno v:
Cancer Research. 80:2779-2779
Introduction: Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancers (PCa) and a target for the development of a variety of therapeutics. Knowledge of how those therapeutics engage tumor PSMA could improve dose finding and